+

US7009069B2 - Intermediates for use in retinoid synthesis - Google Patents

Intermediates for use in retinoid synthesis Download PDF

Info

Publication number
US7009069B2
US7009069B2 US10/399,910 US39991003A US7009069B2 US 7009069 B2 US7009069 B2 US 7009069B2 US 39991003 A US39991003 A US 39991003A US 7009069 B2 US7009069 B2 US 7009069B2
Authority
US
United States
Prior art keywords
synthesis
compound
formula
chem
cdcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/399,910
Other versions
US20040132796A1 (en
Inventor
Alain Valla
Dominique Cartier
Roger Labia
Pierre Jean-Paul Potier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of US20040132796A1 publication Critical patent/US20040132796A1/en
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VALLA, ALAIN, CARTIER, DOMINIQUE, LABIA, ROGER, POTIER, PIERRE JEAN-PAUL
Priority to US11/317,198 priority Critical patent/US7148372B2/en
Priority to US11/317,200 priority patent/US7323589B2/en
Application granted granted Critical
Publication of US7009069B2 publication Critical patent/US7009069B2/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/08—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/10—Formation of amino groups in compounds containing carboxyl groups with simultaneously increasing the number of carbon atoms in the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C07C403/16—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms not being part of —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/313—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of doubly bound oxygen containing functional groups, e.g. carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the subject of the present invention is novel intermediates which are useful for the synthesis of retinoids and carotenoids, and their preparation. It also relates to a novel method for the synthesis of retinoids, in particular retinoic acid and vitamin A or retinol via the retinoic acid thus obtained.
  • Retinoids in particular vitamin A
  • Retinoids are used in various fields, in particular in the therapeutic field, the cosmetic field and in the agro-foodstuffs sector and many methods of synthesis have been used.
  • ⁇ vitamin A derivatives were prepared by condensation of ethyl 3-methylcrotonate with ⁇ -ionylideneacetaldehyde (P. S. Marchand, R. Rüegg, U. Schwieter, P. T. Siddons and B. C. L. Weddon, J. Chem. Soc . (1965), 2019).
  • esters of retinoic acid have been prepared using:
  • Retinonitrile and acetate of vitamin A have been prepared using:
  • Retinal has also been synthesized by:
  • Retinoic acid and the corresponding ethyl ester have been synthesized by the same route by respectively substituting ⁇ -formylcrotonic acid or ethyl ⁇ -formylcrotonate for ⁇ -acetoxytiglaldehyde (patent DE 1 058 710; H. Pommer and W. Sarnecki, Chem. Abstr . (1961), 55, 12, 446; patent DE 1 046 612; H. Pommer and W. Sarnecki, Chem. Abstr . (1961), 55, 5573; patent DE 1 059 900; H. Pommer and W. Sarnecki, Chem. Abstr . (1961), 55, 14, 511; patent DE 1 068 702; H. Pommer and W. Sarnecki, Chem. Abstr . (1961), 55, 10, 812).
  • 9Z-retinoic acid was prepared from the C-15 phosphonium salt derived from ⁇ -(Z)-ionylideneethanol (patent DE 1 068 710; H. Pommer and W. Sarnecki, Chem. Abstr . (1961), 55, 12, 446).
  • pattern DE 1 068 710 H. Pommer and W. Sarnecki, Chem. Abstr . (1961), 55, 12, 446.
  • the synthesis of retinoic acid (and its esters) which is industrially used by BASF uses a Wittig reaction between phosphorane and a C-5 aldehyde (H. Pommer and W. Sarnecki, already cited), said phosphorane being synthesized by the action of triphenylphosphine on ⁇ -ionol.
  • the first stereoselective synthesis of 11Z, 13Z-retinoic acid was carried out in 1965 by Pattenden et al., by the Wittig reaction between phosphorane (generated from ⁇ -ionylideneethyltriphenylphosphonium bromide) and 4-hydroxy-3-methyl-2-buten-4-olide (G. Pattenden, B. C. L. Weedon, C. F. Garbers, D. F. Schneider and J. P. van der Merwe, Chem. Commun . (1965) 347).
  • the reaction mixture changes, leading to a mixture of retinoic acids which can be separated by fractional crystallization.
  • R. W. Dugger and C. H. Heathcock prepared lactones by the action of the dienolate (derived from ethyl senecioate) on E- and Z- ⁇ -ionylideneacetaldehyde.
  • Olson et al. have described a preparation of all-trans-vitamin A (in acetate form), starting with all-trans C-15 bromotriene, prepared from vinyl- ⁇ -ionol, and C-5 tolyl sulfone (G. L. Olson, H. C. Cheung, K. D. Morgan, C. Neukom and G. Saucy J. Org. Chem . (1976), 41, 3287).
  • Manchand et al. report a sequence using another unit in C-5, with the C-15 sulfone, for the synthesis of retinyl acetate.
  • the ⁇ complex of allylpalladium/prenyl acetate is stereoselectively alkylated at the ⁇ position with the anion of the sulfone (P. S. Manchand, H. S. Wong and J. F. Blount J. Org. Chem . (1978), 43, 4769 ⁇ 74).
  • the Hoffmann-La Roche strategy is derived from the Isler technique (O. Isler, W. Huber, A. Ronco and M. Kofler Helv. Chim. Acta (1947), 30, 1911; O. Isler, A. Ronco, W. Guex, N. C. Hindley, W. Huber, K. Dialer and M. Kofler, Helv. Chim. Acta (1949), 32, 489) and uses a synthon in C-14 and a synthon in C-6.
  • the synthon used for the extension of the chain is prepared in 4 steps.
  • the inventors set themselves the objective of synthesizing compounds which are useful as intermediates in the synthesis of retinoids and of their derivatives, in particular in that of retinoic acid and of vitamin A, which are easy to use.
  • G represents:
  • R 1 represents:
  • n is an integer between 1 and 6
  • R 2 and R 3 represent identical or different substituents in each of the unsaturated units, it being possible moreover for said successive unsaturated units to be identical or different, R 2 and R 3 being chosen from the group comprising hydrogen, linear or branched alkyl groups (of 1 to 5 carbon atoms), and aryl groups, it being possible for said alkyl and aryl groups to be substituted,
  • At least one of Y 1 and Y 2 represents a group —COOR 7 and the other is chosen from the group comprising the groups —COR 6 , —CN, —COOR 7 , —CONR 8 R 9 where R 6 and R 7 are each an alkyl group (of 1 to 5 carbon atoms) and R 8 and R 9 are each a linear or branched alkyl group (of 1 to 5 carbon atoms),
  • halogen is understood to mean in particular iodine, bromine, chlorine and fluorine.
  • aryl group is understood to mean a benzene or bicyclic ring.
  • phenyl and naphthyl groups it being possible for said groups to be substituted.
  • cycloalkyl group is understood to mean a ring of 1 to 7 carbon atoms, saturated or containing one or two unsaturations, optionally substituted with one or more alkyl groups (of 1 to 4 carbon atoms).
  • alkyl groups of 1 to 4 carbon atoms.
  • the expression group protecting the hydroxyl functional group is understood to mean groups such as those defined by T. W. Greene in “ Protective groups in organic synthesis ” (John Wiley Interscience, Ed. 2 nd Ed., 1991).
  • groups such as those defined by T. W. Greene in “ Protective groups in organic synthesis ” (John Wiley Interscience, Ed. 2 nd Ed., 1991).
  • alkyl ethers silylated ethers, phosphorus-containing ethers, esters, carbonates and sulfonates.
  • the unsubstituted monoethylenic derivative (1-b) has been synthesized by Regitz M. and Himbert G. ( Justus Liebigs Ann. Chem . (1970), 734, 70–85) and more recently by Gabbutt C., Hepworth J., Heron B., Elsegood M. and Clegg W. ( Chem. Commun . (1999), 3, 289–90).
  • the unsubstituted monoethylenic derivative (1-f) has been widely described and used, in particular for the synthesis of the corresponding enamines or of heterocycles (Yamashkin S. and Yurovskaya M. Chem. Heterocycl. Compd., Engl. Transl . (1997), 33, 1284–87; Glushkov R., Vozyakova T., Adamskaya E., Gus'kova T. et al. Pharm. Chem. J., Engl. Transl ., (1998), 32, 8–12; Kim Y., Kwon T., Chung S. and Smith M. Synth. Commun . (1999), 29, 343–50).
  • the unsubstituted diethylenic derivative (1-g) has been synthesized in particular by Engel C. et al. Can. J. Chem . (1973), 51, 3263–71; Overman L. and Robichaud A. J. Am. Chem. Soc . (1989), 111, 300–308; Krasnaya Zh., Stytsenko T. and Bogdanov V. Bull. Acad. Sci. USSR Div. Chem. Sci., Engl. Transl . (1990), 39, 2316–21; Gelin R. and Makula D. Bull. Soc. Chim. Fr . (1968), 1129–35; de Bie D., Geurtsen B., Berg I., and van der Henk C. J. Org. Chem . (1896), 51, 3209–11.
  • the dimethyl derivative (1-x) has been synthesized by Bogdanov et al., Bull. Acad. Sci. USSR Div. Chem. Sci . (Engl. Transl.) (1990), 39, 298–306 and 1172–80.
  • the compounds of formula (1) are those for which:
  • the compounds of formula (1) are those for which,
  • the compounds are chosen from the group consisting of: and the ethyl ester analogs of the compounds (1-i) to (1-j) and (1-l) to (1-o).
  • the compounds according to the invention may be prepared by techniques known to persons skilled in the art, starting with products of formula (3) in which R 1 , R 2 and R 3 , Y 1 and Y 2 are as defined above and R represents an alkyl group (of 1 or 2 carbon atoms), which are commercially available or which can be obtained by methods described in the literature, or by the method described in the present application.
  • the compounds 1-i, 1-l, 1-m and 1-n may be prepared from N,N-dimethylacetamide dimethyl acetal of formula (2-b)
  • N,N-dimethylformamide or equivalent derivatives which are suitable for use, may be chosen from the group consisting of: the complex: N,N-dimethylformamide-dimethylsulfate; they can also be prepared by the simultaneous or successive action of ethyl or methyl orthoformate or of ethyl or methyl orthoacetate and of a secondary amine HNR 4 R 5 .
  • the compounds of formula (1) with R 1 ⁇ R 2 ⁇ H and R 3 ⁇ CH 3 may be prepared by reacting acetylacetaldehyde dimethyl acetal with a compound possessing a diactivated methylene, in the presence of a secondary amine, according to the following scheme
  • Y 1 , Y 2 , R 4 and R 5 are as defined above.
  • the subject of the present invention is also a method for synthesizing a compound of formula (1) comprising n+1 units from a compound (1) comprising n units, characterized in that an organometallic such as, for example, an alkyl- or arylmagnesium halide or an alkyl- or aryllithium is reacted, in a solvent such as, for example, tetrahydrofuran (THF), dimethoxyethane (DME), ethyl ether and tert-butyl methyl ether, with a compound of formula (1) comprising n units, in order to obtain a compound of formula (3) which is treated with a compound of formula (2) and a compound of formula (1) comprising n+1 units is obtained.
  • an organometallic such as, for example, an alkyl- or arylmagnesium halide or an alkyl- or aryllithium
  • a solvent such as, for example, tetrahydrofuran (THF), dimeth
  • the subject of the present invention is also a method for synthesizing a compound of formula (1) comprising n+2 units from a compound of formula (1) comprising n units, characterized in that the compound of formula (1) comprising n units is reacted, in a solvent such as, for example, tetrahydrofuran (THF), dimethoxyethane (DME), ethyl ether and tert-butyl methyl ether, with the enolate of a ketone, preferably acetone or butanone, said enolate being generated by a base such as, for example, sodium hydride, lithium diisopropylamide, and then an organometallic such as, for example, an alkyl- or arylmagnesium halide or an alkyl- or aryllithium is added, and the compound of formula (3) obtained is treated with a compound of formula (2) and a compound of formula (1) comprising n+2 units is obtained.
  • a solvent such as, for example
  • the subject of the present invention is also a method for preparing an aldehyde of formula (4) in which R 2 , R 3 , Y 1 and Y 2 are as defined above, characterized in that a compound of formula (1) is caused to react preferably in an aqueous acidic medium (in particular 1 to 2 M HCl) or in formic acid in a heterogeneous phase.
  • a compound of formula (1) is caused to react preferably in an aqueous acidic medium (in particular 1 to 2 M HCl) or in formic acid in a heterogeneous phase.
  • the subject of the present invention is also a method for synthesizing retinoids, characterized in that a compound of formula (1) is used as intermediate.
  • a compound of formula (1) with a compound of formula (5) in which Z is chosen from the group comprising the following radicals:
  • the synthesis is carried out in the presence of a base, preferably chosen from the group consisting of alkali metal amides, hydrides and alcoholates.
  • Z contains an oxygenated functional group (CO, HO and the like)
  • a protected form of this functional group as defined in Protective Groups in Organic Synthesis (T. W. Greene, 2 nd Ed., (1991), Wiley Interscience, Ed.) may be used.
  • the base is lithium diisopropylamide optionally combined with N,N,N′,N′-tetramethylethylenediamine or 1,1,1,3,3,3-hexamethyldisilazane.
  • the reaction is carried out in a solvent chosen in particular from the group consisting of 1,2-dimethoxyethane (DME), tert-butyl methyl ether, tetrahydrofuran (THF), ether and mixtures thereof.
  • a solvent chosen in particular from the group consisting of 1,2-dimethoxyethane (DME), tert-butyl methyl ether, tetrahydrofuran (THF), ether and mixtures thereof.
  • the ⁇ -ionone enolate of formula (5-a) is reacted with the compound of formula (1-j) to give a compound of formula (6-a), in the form of a mixture of 2 isomers.
  • This derivative is treated with an organometallic derivative (for example CH 3 MgBr) to give a compound of formula (7-a), in the form of a mixture of 2 isomers
  • organometallic derivative for example CH 3 MgBr
  • This acid is accompanied by its 13-Z isomer, in negligible proportions ( ⁇ 5%).
  • the traces of 13-Z isomer are removed during crystallization of the all-trans-retinoic acid.
  • the subject of the present invention is also a method for preparing vitamin A:
  • the subject of the present invention is also the use of the compounds of formula (1) as intermediates in the synthesis of retinoids and carotenoids, in particular in the synthesis of retinoic acids and vitamin A.
  • the subject of the present invention is more specifically the use of the compound of formula (1-j) in the synthesis of retinoids and carotenoids.
  • the retinoid is chosen from the group consisting of retinoic acid, vitamin A (retinol), retinal, retinonitrile and etretinate.
  • Examples 1a to 1i relate to the preparation of the compounds of formula (1) containing (n+1) units from the compounds of formula (3) containing n units.
  • Examples 2a and 2c relate to the preparation of the compounds of formula (1) according to the second method.
  • Examples 3a to 3j illustrate the method for preparing the compounds of formula (3) which are useful for preparing the compounds of formula (1) containing n+1 or n+2 units, from the compounds of formula (1) containing n units according to Examples 1a to 1i.
  • Examples 4a to 4c illustrate the use of the compounds of formula (1) to prepare the corresponding aldehydes.
  • Examples 5 to 8 illustrate the synthesis of retinoids from the compounds of formula (1).
  • the synthesis is carried out according to protocol x.
  • the synthesis is carried out according to protocol y.
  • the enamino ester obtained is crystallized from pentane and the product is obtained in the form of beige crystals.
  • This product is synthesized according to a method derived from that described by Köechritz (already cited). 15.3 g (0.01 mol) of ethyl 2-cyano-3-methylcrotonate obtained according to the method described by Wideqvist ( S. Acta Chem. Scand . (1949), 3, 303), 600 mg of acetic acid and 11.9 g (0.01 mol) of DMFDMA are mixed. The medium is heated for 2 h at 70° C. in order to remove the methanol and then at 100° C. The reaction is monitored by thin-layer chromatography (TLC) (CH 2 Cl 2 —MeOH 98: 2, rf: 0.7). The enamino ester is crystallized from ether and it is obtained in the form of yellow crystals.
  • TLC thin-layer chromatography
  • the synthesis is carried out according to the protocol y.
  • the dimethylformamide (dimethyl acetal) in excess is distilled off under reduced pressure and the enamino ester obtained is crystallized from ether.
  • the product is obtained in the form of orange yellow crystals.
  • the synthesis is carried out according to the protocol y.
  • the dimethylformamide (dimethyl acetal) in excess is distilled off under reduced pressure and the enamino ester obtained is crystallized from ether.
  • the product is obtained in the form of orange yellow crystals.
  • the synthesis is carried out according to the protocol y.
  • the dimethylformamide (dimethyl acetal) in excess is distilled off under reduced pressure and the enamino ester obtained is crystallized from ethyl acetate.
  • the product is obtained in the form of orange-colored crystals.
  • the synthesis is carried out according to the protocol y.
  • the dimethylformamide (dimethyl acetal) is distilled off under reduced pressure.
  • the product is obtained in the form of an orange yellow oil. Yield>75%.
  • the synthesis is carried out according to the protocol y with dimethylacetamide (dimethyl acetal).
  • the dimethylacetamide (dimethyl acetal) is distilled off under reduced pressure.
  • the product is obtained in the form of a crystallized red product. Yield>50%.
  • the enamino ester is crystallized from ether and it is obtained in the form of yellow crystals. (Yield>50%).
  • an alkylmagnesium halide for example methylmagnesium chloride or bromide (3 M in tetrahydrofuran (THF)
  • 10 mmol of enamine (1) comprising n units, for example the compound (1-j) in 20 ml of THF.
  • the medium is left at room temperature for 1 h 30 min.
  • the medium is cooled to around ⁇ 0° C. and 1 ml of ethanol is added.
  • the medium is slightly acidified with 1 M HCl and the impurities are extracted with ether.
  • a basic medium is obtained by adding aqueous ammonia, at around 0° C.
  • the medium is extracted with dichloromethane, washed with water and dried over sodium sulfate.
  • the crude product is dissolved in 15 ml of toluene and heated for 30 min at boiling temperature. After evaporation under reduced pressure, the product is isolated. This product, treated with DMFDMA, makes it possible to prepare the compound of formula (1) comprising n+1 units.
  • the medium is cooled to a temperature between ⁇ 10 and 0° C. and 20 mmol of methylmagnesium chloride (3 M in THF) are added.
  • the reaction is allowed to return to room temperature.
  • 1 ml of ethanol is added, at 0° C., and then the medium is acidified with 1 M HCl. It is extracted with dichloromethane, washed with 1 M HCl and then with water. After drying over MgSO 4 , the product is isolated after distillation of the solvents under reduced pressure. This product, treated with DMFDMA, makes it possible to prepare the compound of formula (1) comprising n+2 units.
  • Example 3a Starting with the compound prepared in Example 2, the method of Example 3a is used.
  • Example 3a Starting with the compound obtained in Example 1g, the method of Example 3a is used.
  • the compound (1-y) is obtained according to the technique used by H. Merwein Justus Liebigs Ann. Chem. 1961, 641, 1–39. Starting with it, the compound (3-l) is obtained according to the method described in Example 3b.
  • the medium is cooled to a temperature between ⁇ 10 and 0° C. and 20 mmol of alkyl- or arylmagnesium halide (3 M in THF) ae added.
  • the medium is allowed to return to room temperature over 30 minutes and 15 ml of ethanol and then 5 equivalents of potassium hydroxide in 50 ml of water are added at 0° C.
  • the medium is stirred for 30 minutes at room temperature and for 45 minutes at 40° C.
  • the organic solvents are distilled off under reduced pressure.
  • the medium is acidified with a 2 N ice-cold hydrochloric acid solution. It is extracted with ethyl acetate, washed with 1 M hydrochloric acid and then washed with water and dried over sodium sulfate.
  • the yield after purification is equal to 61%.
  • the physicochemical characteristics are identical to those of a reference sample (SIGMA).
  • the yield of crude product is equal to 75%.
  • the crude product is extracted with a saturated bicarbonate solution. After acidification and extraction with ether, the product is purified by chromatography on silica and obtained in the form of a yellow liquid.
  • the yield of purified product is equal to 25%.
  • Example 5 The general method described in Example 5 is used. TLC: rf: 0.35 (CH 2 Cl 2 /MeOH 95/5). Yield after purification 7 g (52%).
  • the product is obtained in the form of a mixture of isomers in which the all-trans isomer is very predominant.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Vapour Deposition (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The invention concerns compounds of formula (1) wherein in particular G represents the —N(CH3)2—, —N(C2H5)2— group or N-pyrrolidine: n is an integer equal to 1 or 2: R1, R2 and R3, independently of one another, represent a hydrogen atom or a methyl group, the successive unsaturated units capable of being moreover identical or different, provided that at least one of the substituents R1, R2 and R3 is different from H; and Y1 and Y2 represent each a —COOCH3 group or a —COOC2H5 group.

Description

The subject of the present invention is novel intermediates which are useful for the synthesis of retinoids and carotenoids, and their preparation. It also relates to a novel method for the synthesis of retinoids, in particular retinoic acid and vitamin A or retinol via the retinoic acid thus obtained.
Retinoids, in particular vitamin A, are used in various fields, in particular in the therapeutic field, the cosmetic field and in the agro-foodstuffs sector and many methods of synthesis have been used.
Many methods of preparation have been used for the synthesis of retinoids, in particular for that of retinoic acid and vitamin A and a recent article relating to industrial techniques which make it possible to obtain vitamin A has been described by Paust J. (Pure & Appl. Chem. (1991), 63, 45–58).
The first synthesis of retinoids belonging to the vitamin A family was described by R. Kuhn and C. J. O. R. Morris (Ber. (1937), 70, 853).
The condensation of β-ionylideneacetaldehydes with ethyl 3-methylcrotonate leads to different retinoic acids, depending on the configuration of the aldehyde, the nature of the solvent and the base used for generating the anion (M. Matsui, S. Okano K. Yamashita, M. Miyano, S. Kitamura, A. Kobayashi, T. Sato and B. R. Mikami J. Vitaminol. (Kyoto), (1958), 4, 178).
These same isomers have been synthesized by a similar route from various C-15 aldehydes and methyl β-methylglutaconates (C. D. Robeson, J. D. Cawley, L. Weisler, M. H. Stern, C. C. Eddinger and A. J. Chechak, J. Am. Chem. Soc. (1955), 77, 4111).
The synthesis of 13Z-retinoic acid has also been carried out by a Réformatskii reaction between the C-15 aldehyde and methyl γ-bromo-β-methylcrotonate (Eiter, E. Truscheit and H. Oediger, Angew. Chem. (1960), 72, 948).
The reduction of the various C-20 methyl esters, with LiAlH4, leads to the corresponding isomers of vitamin A. Retinal is obtained from the latter by oxidation (U.S. Pat. No. 3,367,985; J. D. Surmatis, S. Ball, T. W. Goodwin at R. A. Morton, Biochem. J. (1948), 42, 516; C. D. Robertson, W. P. Blum, J. M. Dieterle, J. D. Cawley and J. G. Baxter J. Am. Chem. Soc. (1995), 77, 4120).
Similarly, the α vitamin A derivatives were prepared by condensation of ethyl 3-methylcrotonate with α-ionylideneacetaldehyde (P. S. Marchand, R. Rüegg, U. Schwieter, P. T. Siddons and B. C. L. Weddon, J. Chem. Soc. (1965), 2019).
The Wittig and Horner reactions, starting with the C-15 aldehyde, have been widely used for the synthesis of many vitamin A derivatives.
Thus, the esters of retinoic acid have been prepared using:
    • the phosphonium salt derived from methyl γ-bromo-β-methylcrotonate (patent DE 950 552; G. Wittig and H. Pommer, Chem. Abstr. (1959), 53, 436), and
    • the phosphonate equivalent (H. Pommer, Angew. Chem. (1960), 72, 811).
Retinonitrile and acetate of vitamin A have been prepared using:
    • the phosphonium salt derived from γ-bromo-β-crotonitrile (H. Pommer, Angew. Chem. (1960), 72, 811), and
    • the corresponding phosphonate (patent DE 1 116 652; H. Pommer and W. Stilz, Chem. Abstr. (1962), 57, 2267).
Retinal has also been synthesized by:
    • a Wittig reaction with (4,4-diethoxy-2-methyl-2-butenyl)triphenylphosphonium bromide,
    • condensation of the diethyl acetal of β-ionylideneacetaldehyde with 1-ethoxy-3-methyl-1,3-butadiene (S. M. Makin, Russ. Chem. Rev. (Engl. Transl.) (1969), 38, 237), and
    • oxidation according to Oppenauer of a mixture of β-ionylideneethanol and β,β-dimethylallyl alcohol (patent JP 5145/58; M. Matsui and S. Kitamura, Chem. Abstr. (1959), 53, 17, 178).
The method developed by H. Pommer (Angew. Chem. (1960), 72, 811), currently used by the company Badische Anilin & Soda Fabrik AG (BASF) uses a Wittig reaction between (β-ionylideneethyl)triphenylphosphonium chloride and γ-acetoxytiglaldehyde, in the presence of sodium methoxide. The reaction product consists of a mixture of all-E and 11Z acetates from which the all-E isomer is obtained by crystallization (patent DE 1 058 710; H. Pommer and W. Sarnecki, Chem. Abstr. (1961), 55, 12, 446; patent DE 1 046 612; H. Pommer and W. Sarnecki, Chem. Abstr. (1961), 55, 5573 and patent DE 1 059 900; H. Pommer and W. Sarnecki, Chem. Abstr. (1961), 55, 14, 511).
Retinoic acid and the corresponding ethyl ester have been synthesized by the same route by respectively substituting β-formylcrotonic acid or ethyl β-formylcrotonate for γ-acetoxytiglaldehyde (patent DE 1 058 710; H. Pommer and W. Sarnecki, Chem. Abstr. (1961), 55, 12, 446; patent DE 1 046 612; H. Pommer and W. Sarnecki, Chem. Abstr. (1961), 55, 5573; patent DE 1 059 900; H. Pommer and W. Sarnecki, Chem. Abstr. (1961), 55, 14, 511; patent DE 1 068 702; H. Pommer and W. Sarnecki, Chem. Abstr. (1961), 55, 10, 812).
9Z-retinoic acid was prepared from the C-15 phosphonium salt derived from β-(Z)-ionylideneethanol (patent DE 1 068 710; H. Pommer and W. Sarnecki, Chem. Abstr. (1961), 55, 12, 446). Thus, the synthesis of retinoic acid (and its esters) which is industrially used by BASF uses a Wittig reaction between phosphorane and a C-5 aldehyde (H. Pommer and W. Sarnecki, already cited), said phosphorane being synthesized by the action of triphenylphosphine on β-ionol.
The first stereoselective synthesis of 11Z, 13Z-retinoic acid was carried out in 1965 by Pattenden et al., by the Wittig reaction between phosphorane (generated from β-ionylideneethyltriphenylphosphonium bromide) and 4-hydroxy-3-methyl-2-buten-4-olide (G. Pattenden, B. C. L. Weedon, C. F. Garbers, D. F. Schneider and J. P. van der Merwe, Chem. Commun. (1965) 347). The reaction mixture changes, leading to a mixture of retinoic acids which can be separated by fractional crystallization. Controlled isomerization of 11Z,13Z-retinoic acid leads respectively to 13Z- or all-E-retinoic acids (G. Pattenden and B. C. L. Weedon, J. Chem. Soc. C (1968), 1984; C. F. Garbers, D. F. Schneider and J. P. van der Merwe, J. Chem. Soc. C (1968), 1982).
A similar approach, described by G. Cainelli and G. Cardillo (Acc. Chem. Res. (1981), 14, 89) and G. Cainelli, G. Cardillo, M. Contendo, P. Grasselli and A. Umani Ronchi (Gazz. Chim. Ital. (1973), 103, 117) uses the reaction of dienolate (derived from the sodium salt of senecioic acid) on the C-15 aldehyde.
Alternatively, R. W. Dugger and C. H. Heathcock (J. Org. Chem., (1980), 45, 1181) prepared lactones by the action of the dienolate (derived from ethyl senecioate) on E- and Z-β-ionylideneacetaldehyde.
G. Cardillo, M. Contendo and S. Sandri, (J. Chem. Soc. Perkin I (1979), 1729) have proposed a stereospecific synthesis of all-trans-retinal via β-ionylideneacetaldehyde and the dianion derived from 3-methyl-3-butenol.
The preparation of vitamin A and that of the ethyl ester of retinoic acid were also carried out by condensation of methyl β-formylcrotonate with the C-15 Grignard derivatives (K. K. Chugai Seiyaku Derwent Farmdoc (1964), 11, 643; K. Shishido, H. Nozaki and M. Tsuda, Derwent Farmdoc, (1964), 11, 669).
The condensation of the bis(2,2,2-trifluoroethyl)phosphonate anion (generated by potassium hexamethyldisilazide/18-crown-6) with 7Z,9Z-β-ionylideneacetaldehyde leads to the mixture of the 7Z,9Z-, 7Z,9Z,11Z-, 7Z,9Z,13Z- and 7Z,9Z,11Z,13Z-retinonitriles, which may be separated by high-performance liquid chromatography (HPLC) (A. Trehan, T. Mirzadegan and R. S. H. Liu, Tetrahedron, (1990), 46, 3769; W. C. Still and C. Gennari, Tetrahedron Lett. (1983), 24, 4405).
Other authors used the benzoic ester of 7Z-ethynylcarbinol to prepare 11Z-18,14-retroretinol. The photochemical isomerization of ethynyl-β-ionol made it possible to obtain the compound possessing a C-7 Z configuration (Y. S. Chauhan, R. A. S. Chandraratna, D. A. Miller, R. W. Kondrat, W. Reischl and W. H. Okamura, J. Am. Chem. Soc. (1985), 107, 1028). The hydrolysis of benzoate with a base, such as for example 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), allows the formation of the retrosystem.
The condensation of the C-15 aldehyde of E configuration, with diethyl isopropylidenemalonate followed by the hydrolysis of the ester, gave 14-carboxyretinoic acid (Y. F. Shealy, C. A. Krauth, J. M. Riodan and B. P. Sani, J. Med. Chem. (1988), 31, 1124).
The condensation of β-ionylideneacetaldehyde, dimethylacetal with trimethylsilyldienol ether or ethyl-dienol ether, catalyzed by a Lewis acid, gives the mixture of 11-methoxy- and 11,12-dihydroretinals which, by removal of methanol under the action of a base followed by isomerization (I2), produces the all-trans-retinal (T. Mukaiyama and I. Ishida Chem. Lett. (1975), 1201).
M. Julia and D. Arnould (Bull. Soc. Chim. Fr. (1973), 746) have reported a stereoselective synthesis in which the tetraenic chain is generated by alkylation via a sulfinic acid, followed by removal of said acid.
This synthesis has been repeated by the companies Hoffmann-La Roche (P. S. Manchand, M. Rosenberg, G. Saucy, P. A. Wehrli, H. Wong, L. Chambers, M. P. Ferro and W. Jackson, Helv. Chim. Acta (1976), 59, 387) and Rhône Poulenc Industries (P. Chabardes, J. P. Décor and J. Varagnat, Tetrahedron Lett. (1977), 33, 2799) for the production of vitamin A in the all-trans form and of the corresponding acetate (for the latter, starting with C-5 chloroacetate). The stereoselectivities being from 9E:9Z≃73:27 to 82:18.
Olson et al. have described a preparation of all-trans-vitamin A (in acetate form), starting with all-trans C-15 bromotriene, prepared from vinyl-β-ionol, and C-5 tolyl sulfone (G. L. Olson, H. C. Cheung, K. D. Morgan, C. Neukom and G. Saucy J. Org. Chem. (1976), 41, 3287). Manchand et al. report a sequence using another unit in C-5, with the C-15 sulfone, for the synthesis of retinyl acetate. The π complex of allylpalladium/prenyl acetate is stereoselectively alkylated at the δ position with the anion of the sulfone (P. S. Manchand, H. S. Wong and J. F. Blount J. Org. Chem. (1978), 43, 4769∝74).
By photoisomerization of these compounds, it is possible to obtain the 7Z;7Z, 11Z;7Z, 13Z;7Z,9Z,11Z and all-Z isomers (R. S. H. Liu and A. E. Asato Tetrahedron Lett. (1984), 40, 1931).
A recent synthesis also makes it possible to prepare the 13Z and 13E-retinoic acids by the use of novel synthons β-methylenealdehydes, by condensation according to Stobbe with methyl isopropylidenemalonate, in the presence of Triton B (Patent Application EP 0 802 180; Giraud M. et al.).
Currently, the three main industrial syntheses use β-ionone as starting material.
The Hoffmann-La Roche strategy is derived from the Isler technique (O. Isler, W. Huber, A. Ronco and M. Kofler Helv. Chim. Acta (1947), 30, 1911; O. Isler, A. Ronco, W. Guex, N. C. Hindley, W. Huber, K. Dialer and M. Kofler, Helv. Chim. Acta (1949), 32, 489) and uses a synthon in C-14 and a synthon in C-6.
The synthon in C-6 which is used is itself prepared in 3 steps.
Another industrial synthesis developed by Badische Anilin & Soda Fabrik AG (BASF) is based on the method of Inhoffen and Pommer (H. Pommer Angew. Chem. (1960), 72, 811).
The synthon used for the extension of the chain is prepared in 4 steps.
The synthesis of vitamin A carried out by Rhône Poulenc Rorer (RPR) is adapted from the Julia technique (Julia M. and Arnould D. Bull. Soc. Chim. (1973), 746).
In this method, a synthon in C-6 prepared in 4 steps is used.
All the industrial methods recalled above use dangerous and/or toxic reagents, in particular sodium in liquid ammonia, organometallics, aluminum hydrides, phosphorus oxychloride, chlorine and pyridine; they also require the use of catalytic hydrogenation steps which are particularly dangerous. The preparation of the synthons comprises several steps and all these methods require, in addition, the use of purification steps in order to remove by-products, which makes these methods long and expensive.
Given the importance of retinoids and the derivatives thereof, in particular that of retinoic acid and vitamin A, it is essential to find methods of synthesis which overcome or limit these disadvantages.
Accordingly, the inventors set themselves the objective of synthesizing compounds which are useful as intermediates in the synthesis of retinoids and of their derivatives, in particular in that of retinoic acid and of vitamin A, which are easy to use.
The subject of the present invention is compounds of formula (1)
Figure US07009069-20060307-C00001
in which
G represents:
    • either a halogen atom,
    • or a group —NR4R5 where R4 and R5, which are identical or different, are each a linear or branched alkyl group (of 1 to 5 carbon atoms), or a substituted or unsubstituted, saturated or unsaturated cycloalkyl group (of 3 to 7 carbon atoms), or a substituted or unsubstituted aryl group, or R4 and R5 form a ring with the nitrogen atom carrying them,
    • or a group OP where P is a group protecting the hydroxyl functional group, provided that OP is not included in a bond where Y1 or Y2,
    • or a group SR, SOR or SO2R where R is a linear or branched alkyl group (of 1 to 5 carbon atoms) or a substituted or unsubstituted, saturated or unsaturated cycloalkyl group (of 3 to 7 carbon atoms), or a substituted or unsubstituted aryl group,
R1 represents:
    • either a hydrogen atom,
    • or a linear or branched alkyl group (of 1 to 5 carbon atoms),
n is an integer between 1 and 6,
R2 and R3 represent identical or different substituents in each of the unsaturated units, it being possible moreover for said successive unsaturated units to be identical or different, R2 and R3 being chosen from the group comprising hydrogen, linear or branched alkyl groups (of 1 to 5 carbon atoms), and aryl groups, it being possible for said alkyl and aryl groups to be substituted,
provided that at least one of the substituents R1, R2 and R3 is different from H,
at least one of Y1 and Y2 represents a group —COOR7 and the other is chosen from the group comprising the groups —COR6, —CN, —COOR7, —CONR8R9 where R6 and R7 are each an alkyl group (of 1 to 5 carbon atoms) and R8 and R9 are each a linear or branched alkyl group (of 1 to 5 carbon atoms),
with the exception of the following compounds of formula (1) where n=1 and:
    • R1=CH3, R2=R3=H, G=N (CH3)2, Y1=COOCH3, Y2=COCH3.
    • R1=CH3, R2=R3=H, G=N (C2H5)2, Y1=COOCH3, Y2=COCH3.
    • R1=CH3, R2=R3=H, G=N (C2H5)2, Y1=COOC2H5, Y2=COCH3.
    • R1=H, R2=CH3, R3=H, G=OCH3, Y1=Y2=COOCH3.
    • R1=H, R2=CH3, R3=H, G=OC2H5, Y1=Y2=COOCH3.
    • R1=H, R2=CH3, R3=H, G=OC2H5, Y1=Y2=COOC2H5.
    • R1=H, R2=CH3, R3=H, G=N (CH3)2, Y1=Y2=COOCH3.
    • R1=H, R2=CH3, R3=H, G=N (CH3)2, Y1=COOCH3, Y2=COCH3.
    • R1=H, R2=CH3, R3=H, G=N (CH3)2, Y1=COOCH3, Y2—CN.
    • R1=H, R2=CH3, R3=H, G=pipéridyl, Y1=COOC2H5, Y2=CN.
    • R1=H, R2=CH3, R3=H, G=N (CH3)2, Y1=COOC2H5, Y2=COC6H5.
    • R1=H, R2=C2H5, R3=H, G=OC2H5, Y1=Y2=COOC2H5.
    • R1=H, R2=iso-propyl, R3=H, G=N (CH3)2, Y1=Y2=COOCH3.
    • R1=H, R2=iso-propyl, R3=H, G=N (CH3)2, Y1=COOCH3, Y2=COCH3.
    • R1=H, R2=iso-propyl, R3=H, G=N (CH3)2, Y1=COOC2H5, Y2=COC6H5.
    • R=R2=H, R3=CH3, G=OC2H5, Y1=COOC2H5, Y2=CN.
    • R=R2=H, R3=CH3, G=N (CH3)2, Y1=COOC2H5, Y2—CN.
and with the exception of the compound of formula (1) where n=2 of the following formula methyl (2-acetyl-7-(dimethylamino)-4-methyl-2,4,6-heptatrienoate:
Figure US07009069-20060307-C00002
For the purposes of the present invention, the expression halogen is understood to mean in particular iodine, bromine, chlorine and fluorine.
For the purposes of the present invention, the expression aryl group is understood to mean a benzene or bicyclic ring. By way of nonlimiting example, there may be mentioned the phenyl and naphthyl groups, it being possible for said groups to be substituted.
For the purposes of the present invention, the expression cycloalkyl group is understood to mean a ring of 1 to 7 carbon atoms, saturated or containing one or two unsaturations, optionally substituted with one or more alkyl groups (of 1 to 4 carbon atoms). By way of nonlimiting example, there may be mentioned the 2,6,6-trimethylcyclohexenyl and 2,6,6-trimethlcyclohexadienyl groups.
For the purposes of the present invention, the expression group protecting the hydroxyl functional group is understood to mean groups such as those defined by T. W. Greene in “Protective groups in organic synthesis” (John Wiley Interscience, Ed. 2nd Ed., 1991). By way of nonlimiting example, there may be mentioned alkyl ethers, silylated ethers, phosphorus-containing ethers, esters, carbonates and sulfonates.
Compounds having a similar structure corresponding to formula (1) for which n=0 are known and described in the literature.
Thus, the unsubstituted monoethylenic derivative (1-a)
Figure US07009069-20060307-C00003
has been synthesized by several authors, in particular by Sorsak G., Grdadolnik S. and Stanovnik B. (Ach. Mod. Chem. (1998), 135, 613–24) from dimethylformamide dimethyl acetal (DMFDMA).
The unsubstituted monoethylenic derivative (1-b)
Figure US07009069-20060307-C00004
has been synthesized by Regitz M. and Himbert G. (Justus Liebigs Ann. Chem. (1970), 734, 70–85) and more recently by Gabbutt C., Hepworth J., Heron B., Elsegood M. and Clegg W. (Chem. Commun. (1999), 3, 289–90).
Some compounds of formula (1) where n=1 are also known and described in the literature.
The synthesis of the unsubstituted diethylenic derivative (1-c) has been described by Krasnaya Zh. et al. (Bull. Acad. Sci. USSR Div. Chem. Sci., Engl. Transl. (1973), 22, 1959–62)
Figure US07009069-20060307-C00005
The synthesis of the substituted diethylenic derivatives (1-d) where R and R′ represent in particular alkyl or aryl groups has been described by Smetskaya N. I., Mukhina N. A. and Granik V. G. (Chem. Heterocycl. Compd., Engl Transl. (1984), 20, 650–53) and Michalik M., Zahn K., Köeckritz P. and Liebscher J. (J. Prakt. Chem. (1989), 331, 1–10; Bull. Acad. Sci. USSR Div. Chem. Sci. Engl. Transl. (1973), 22, 1959–62)
Figure US07009069-20060307-C00006
These same authors also describe compounds (1-e) where R, R′ and R″ represent in particular alkyl or aryl groups.
Figure US07009069-20060307-C00007
However, the compounds (1-d) and (1-e) have never been used in the synthesis of retinoids.
The unsubstituted monoethylenic derivative (1-f)
Figure US07009069-20060307-C00008
has been widely described and used, in particular for the synthesis of the corresponding enamines or of heterocycles (Yamashkin S. and Yurovskaya M. Chem. Heterocycl. Compd., Engl. Transl. (1997), 33, 1284–87; Glushkov R., Vozyakova T., Adamskaya E., Gus'kova T. et al. Pharm. Chem. J., Engl. Transl., (1998), 32, 8–12; Kim Y., Kwon T., Chung S. and Smith M. Synth. Commun. (1999), 29, 343–50).
The unsubstituted diethylenic derivative (1-g)
Figure US07009069-20060307-C00009
has been synthesized in particular by Engel C. et al. Can. J. Chem. (1973), 51, 3263–71; Overman L. and Robichaud A. J. Am. Chem. Soc. (1989), 111, 300–308; Krasnaya Zh., Stytsenko T. and Bogdanov V. Bull. Acad. Sci. USSR Div. Chem. Sci., Engl. Transl. (1990), 39, 2316–21; Gelin R. and Makula D. Bull. Soc. Chim. Fr. (1968), 1129–35; de Bie D., Geurtsen B., Berg I., and van der Henk C. J. Org. Chem. (1896), 51, 3209–11.
The synthesis of the unsubstituted diethylenic derivative (1-h) has also been described by Shramoya Z. et al. (J. Org. Chem. USSR (Engl. Transl.) (1966), 2, 1005–1009) and by Gelin R. and Makula D. (Bull. Soc. Chim. Fr. (1968), 1129–35)
Figure US07009069-20060307-C00010
The dimethyl derivative (1-x)
Figure US07009069-20060307-C00011
has been synthesized by Bogdanov et al., Bull. Acad. Sci. USSR Div. Chem. Sci. (Engl. Transl.) (1990), 39, 298–306 and 1172–80.
However, the compounds (1-f) to (1-h) and (1-x) have never been used in the synthesis of retinoids.
In a particular embodiment of the invention, the compounds of formula (1) are those for which:
    • G represents a group —NR4R5 where R4 and R5, which are identical or different, are each a linear or branched alkyl group (of 1 to 5 carbon atoms), or a cycloalkyl group (of 3 to 7 carbon atoms), or R4 and R5 form a ring with the nitrogen atom carrying them,
    • R1 represents either a hydrogen atom or a linear or branched alkyl group (of 1 to 5 carbon atoms),
    • n is an integer between 1 and 2,
    • R2 and R3 represent a similar or different substituent in each of the unsaturated units, it being possible moreover for said successive unsaturated units to be identical or different, R2 and R3 being chosen from the group comprising hydrogen and the linear or branched alkyl groups (of 1 to 5 carbon atoms), and provided that at least one of the substituents R1, R2 and R3 is different from H, and
    • Y1 and Y2 each represent a group —COOR7 where R7 is an alkyl group (of 1 to 5 carbon atoms).
In another particular embodiment, the compounds of formula (1) are those for which,
    • G represents the group —N(CH3)2, —N(C2H5)2 or N-pyrrolidine,
    • n is an integer equal to 1 or 2,
    • R1, R2 and R3 represent, independently of each other, a hydrogen atom or a methyl group, it being possible moreover for the successive unsaturated units to be identical or different, provided that at least one of the substituents R1, R2 and R3 is different from H, and
    • Y1 and Y2 each represent a group —COOCH3 or a group —COOC2H5.
In an advantageous embodiment according to the invention, the compounds are chosen from the group consisting of:
Figure US07009069-20060307-C00012
and the ethyl ester analogs of the compounds (1-i) to (1-j) and (1-l) to (1-o).
The compounds according to the invention may be prepared by techniques known to persons skilled in the art, starting with products of formula (3)
Figure US07009069-20060307-C00013
in which R1, R2 and R3, Y1 and Y2 are as defined above and R represents an alkyl group (of 1 or 2 carbon atoms), which are commercially available or which can be obtained by methods described in the literature, or by the method described in the present application.
Thus, the compound (1-j) may be prepared by reacting the methyl isopropylidenemalonate of formula (3-a) (n=0, R=R1=CH3 and Y1=Y2=—COOCH3).
Figure US07009069-20060307-C00014
with a protected form of N,N-dimethylformamide, for example dimethyl acetal, of formula (2-a) or DMFDMA
Figure US07009069-20060307-C00015
Likewise, the compounds 1-i, 1-l, 1-m and 1-n, according to the invention, may be prepared from N,N-dimethylacetamide dimethyl acetal of formula (2-b)
Figure US07009069-20060307-C00016
The compounds of formula (1), in which G represents a group —NR4R5 where R4 and R5 are as defined above, may be obtained in a manner similar to those used in the scheme which follows:
Figure US07009069-20060307-C00017
Other protected forms of N,N-dimethylformamide or equivalent derivatives, which are suitable for use, may be chosen from the group consisting of:
Figure US07009069-20060307-C00018
the complex: N,N-dimethylformamide-dimethylsulfate; they can also be prepared by the simultaneous or successive action of ethyl or methyl orthoformate or of ethyl or methyl orthoacetate and of a secondary amine HNR4R5.
Moreover, the compounds of formula (1) with R1═R2═H and R3═CH3 may be prepared by reacting acetylacetaldehyde dimethyl acetal with a compound possessing a diactivated methylene, in the presence of a secondary amine, according to the following scheme
Figure US07009069-20060307-C00019
Y1, Y2, R4 and R5 are as defined above.
The subject of the present invention is also a method for synthesizing a compound of formula (1) comprising n+1 units from a compound (1) comprising n units, characterized in that an organometallic such as, for example, an alkyl- or arylmagnesium halide or an alkyl- or aryllithium is reacted, in a solvent such as, for example, tetrahydrofuran (THF), dimethoxyethane (DME), ethyl ether and tert-butyl methyl ether, with a compound of formula (1) comprising n units, in order to obtain a compound of formula (3) which is treated with a compound of formula (2) and a compound of formula (1) comprising n+1 units is obtained.
In the case where n=1, then the method may be illustrated by the scheme which follows:
Figure US07009069-20060307-C00020
The subject of the present invention is also a method for synthesizing a compound of formula (1) comprising n+2 units from a compound of formula (1) comprising n units, characterized in that the compound of formula (1) comprising n units is reacted, in a solvent such as, for example, tetrahydrofuran (THF), dimethoxyethane (DME), ethyl ether and tert-butyl methyl ether, with the enolate of a ketone, preferably acetone or butanone, said enolate being generated by a base such as, for example, sodium hydride, lithium diisopropylamide, and then an organometallic such as, for example, an alkyl- or arylmagnesium halide or an alkyl- or aryllithium is added, and the compound of formula (3) obtained is treated with a compound of formula (2) and a compound of formula (1) comprising n+2 units is obtained.
In the case where n=1, then the method may be illustrated by the scheme which follows:
Figure US07009069-20060307-C00021
The subject of the present invention is also a method for preparing an aldehyde of formula (4)
Figure US07009069-20060307-C00022
in which R2, R3, Y1 and Y2 are as defined above, characterized in that a compound of formula (1) is caused to react preferably in an aqueous acidic medium (in particular 1 to 2 M HCl) or in formic acid in a heterogeneous phase.
In the case where n=1, said method may be illustrated by the following scheme:
Figure US07009069-20060307-C00023
The subject of the present invention is also a method for synthesizing retinoids, characterized in that a compound of formula (1) is used as intermediate.
In a particular embodiment of said method, it comprises at least one step consisting in reacting a compound of formula (1) with a compound of formula (5)
Figure US07009069-20060307-C00024
in which Z is chosen from the group comprising the following radicals:
Figure US07009069-20060307-C00025
In a particular embodiment of the invention, the synthesis is carried out in the presence of a base, preferably chosen from the group consisting of alkali metal amides, hydrides and alcoholates.
In the case where Z contains an oxygenated functional group (CO, HO and the like), a protected form of this functional group (as defined in Protective Groups in Organic Synthesis (T. W. Greene, 2nd Ed., (1991), Wiley Interscience, Ed.) may be used.
In a very advantageous embodiment of the method according to the invention, the base is lithium diisopropylamide optionally combined with N,N,N′,N′-tetramethylethylenediamine or 1,1,1,3,3,3-hexamethyldisilazane.
In another very advantageous embodiment of the method according to the invention, the reaction is carried out in a solvent chosen in particular from the group consisting of 1,2-dimethoxyethane (DME), tert-butyl methyl ether, tetrahydrofuran (THF), ether and mixtures thereof.
In a particularly advantageous embodiment of the invention, the β-ionone enolate of formula (5-a)
Figure US07009069-20060307-C00026
is reacted with the compound of formula (1-j)
Figure US07009069-20060307-C00027
to give a compound of formula (6-a), in the form of a mixture of 2 isomers.
Figure US07009069-20060307-C00028
This derivative is treated with an organometallic derivative (for example CH3MgBr) to give a compound of formula (7-a), in the form of a mixture of 2 isomers
Figure US07009069-20060307-C00029
It is saponified, preferably with an aqueous-alcoholic solution of potassium hydroxide or of sodium hydroxide to give all-trans-retinoic acid of formula (8).
Figure US07009069-20060307-C00030
This acid is accompanied by its 13-Z isomer, in negligible proportions (<5%). The traces of 13-Z isomer are removed during crystallization of the all-trans-retinoic acid.
The subject of the present invention is also a method for preparing vitamin A:
    • via the acid chloride of retinoic acid, according to methods known to persons skilled in the art, in particular according to the method described by Huisman et al., Recl. Trav. Chim. Pays-Bas (1956), 75, 977–1004,
    • via the methyl or ethyl esters of retinoic acid, according to methods known to persons skilled in the art, in particular according to the method described by Wendler et al., J. Am. Chem. Soc. (1949), 71, 3267; Schwarzkoft et al., Helv. Chim. Acta (1949), 32, 443, 451–452; Ebeson et al., J. Am. Chem. Soc. (1955), 77, 4111–18),
      said method being characterized in that the retinoic acid is prepared according to the method described above.
The subject of the present invention is also the use of the compounds of formula (1) as intermediates in the synthesis of retinoids and carotenoids, in particular in the synthesis of retinoic acids and vitamin A.
The subject of the present invention is more specifically the use of the compound of formula (1-j) in the synthesis of retinoids and carotenoids.
In an advantageous embodiment according to the invention, the retinoid is chosen from the group consisting of retinoic acid, vitamin A (retinol), retinal, retinonitrile and etretinate.
The method according to the invention has many technical and economic advantages:
    • the compounds of formula (1) are easily prepared, in one or two steps, from raw materials which are commercially available, which is not the case in the syntheses known from the literature or in industrial syntheses,
    • the novel synthon enamino diester of formula (1-j) makes it possible to directly obtain, stereoselectively, all-trans-retinoic acid by a “one pot” multistep synthesis whose yield is greater than 60% (nonoptimized), and
    • the preparation is carried out in a single day.
For the synthesis of vitamin A via all-trans-retinoic acid (via the corresponding acid chloride or esters), it can be carried out in two days, which is not the case for the industrial syntheses which are currently used.
Examples which follow illustrate the invention without however being limited to these particular embodiments.
Examples 1a to 1i relate to the preparation of the compounds of formula (1) containing (n+1) units from the compounds of formula (3) containing n units.
Examples 2a and 2c relate to the preparation of the compounds of formula (1) according to the second method.
Examples 3a to 3j illustrate the method for preparing the compounds of formula (3) which are useful for preparing the compounds of formula (1) containing n+1 or n+2 units, from the compounds of formula (1) containing n units according to Examples 1a to 1i.
Examples 4a to 4c illustrate the use of the compounds of formula (1) to prepare the corresponding aldehydes.
Examples 5 to 8 illustrate the synthesis of retinoids from the compounds of formula (1).
EXAMPLE 1 General Procedure for Preparing the Compounds of Formula 1 According to the First Method
15 mmol of DMFDMA are added to 10 mmol of diester,
    • either in the cold state (dropwise), the reaction being monitored by thin-layer chromatography (TLC) and the product isolated by crystallization (protocol x),
    • or at room temperature, the mixture then being heated directly to a temperature which makes it possible to remove by distillation the methanol formed; the reaction is monitored by thin-layer chromatography (TLC). At the end of the reaction, the DMFDMA in excess is removed by distillation under reduced pressure (protocol y).
EXAMPLE 1a Synthesis of the Compound (1-a)
Figure US07009069-20060307-C00031
The synthesis is carried out according to protocol x. The product is obtained in the form of white crystals. Melting point=63° C. (ether).
EXAMPLE 1b Synthesis of the Compound (1-j)
Figure US07009069-20060307-C00032
The synthesis is carried out according to protocol y. The enamino ester obtained is crystallized from pentane and the product is obtained in the form of beige crystals.
(Yield>85%). (rf: CH2Cl2, 0.15). m.p.: 113° C.
By carrying out the procedure in 50 ml of dimethylformamide (DMF) and adding 1 ml of trifluoroacetic acid, the time is brought to 1 h of boiling of DMF. Yield>85%.
IR: 1716; 1686; 1619; 1539; 1433; 1399; 1330; 1191; 1115; 1068; 995; 959. 1H NMR (CDCl3): 6.93 (d, 1H, J=13.2, H4); 6.07 (d, 1H, J=13.2, H5); 3.71 (s, 6H, COOCH3); 2.91 (s, 6H, N—(CH3)2); 2.10 (s, 3H, 3-CH3). 13C NMR (CDCl3) (CO); 167.3 (CH); 148.8; 97.4 (CH3); 52.0; 51.9; 41.0; 16.7.
EXAMPLE 1c Synthesis of the Compound (1-q) from (3, R=R1=CH3, Methyl Ester)
Figure US07009069-20060307-C00033
This product is synthesized according to a method derived from that described by Köechritz (already cited). 15.3 g (0.01 mol) of ethyl 2-cyano-3-methylcrotonate obtained according to the method described by Wideqvist (S. Acta Chem. Scand. (1949), 3, 303), 600 mg of acetic acid and 11.9 g (0.01 mol) of DMFDMA are mixed. The medium is heated for 2 h at 70° C. in order to remove the methanol and then at 100° C. The reaction is monitored by thin-layer chromatography (TLC) (CH2Cl2—MeOH 98: 2, rf: 0.7). The enamino ester is crystallized from ether and it is obtained in the form of yellow crystals.
(Yield>60%). m.p.: 85° C.
IR: 3145; 2180; 1696; 1615; 1526; 1403; 1273; 1238; 1185; 1137; 842. 1H NMR (CDCl3): 7.29 (d, 1H, J=13, H4); 6.1 (d, 1H, J=13, H5), 3.74 (s, 3H, OCH3); 3.18 and 2.98 (2s, flattened, 6H), (t, 3H, N—CH3); 2.30 (s, 3H, 3-CH3).
EXAMPLE 1d Synthesis of the Compound (1-c)
Figure US07009069-20060307-C00034
The synthesis is carried out according to the protocol y. The dimethylformamide (dimethyl acetal) in excess is distilled off under reduced pressure and the enamino ester obtained is crystallized from ether. The product is obtained in the form of orange yellow crystals.
(Yield>75%). (rf: CH2Cl2, 0.15). m.p.: 44° C.
IR: 1684; 1654; 1618; 1555; 1395; 1378; 1218; 1174; 1117; 1071; 1030; 1014. 1H NMR (CDCl3): 7.75 (d, 1H, J=12.5, H5); 6.94 (d, 1H, J=12.5, H3); 6.11 (t, 1H, J=12.5, H4); 4.28 and 4.20 (2q, 4H, CH2); 3.01 (bs, 6H, N—(CH3)2); 1.33 (2q, 6H, CH3). 13C NMR (CDCl3) (CO); 167.1 and 166.9 (CH); 157.0; 154.0; 97.5 (CH2); 60.4; 60.2 (CH3) 14.8; 14.6.
EXAMPLE 1e Synthesis of the Compound (1-k)
Figure US07009069-20060307-C00035
The synthesis is carried out according to the protocol y. The dimethylformamide (dimethyl acetal) in excess is distilled off under reduced pressure and the enamino ester obtained is crystallized from ether. The product is obtained in the form of orange yellow crystals.
(Yield>75%). (rf: CH2Cl2, 0.15). m.p.: 44° C. IR: 1724; 1678; 1619; 1536; 1426; 1390; 1371; 1233; 1169; 1126; 1082; 1023; 918; 881; 761; 726. 1H NMR (CDCl3) : 7.31 (s, 1H, H5); 6.79 (s, 1H, H3); 3.82 and 3.75 (2s, 6H, N—(CH)3); 3.08 (s, 6H, OCH3); 1.83 (s, 3H, CH3). 13C NMR (CDCl3); CH3:51.8; 51.5; 43.3.
EXAMPLE 1f Synthesis of the Compound (1-p)
Figure US07009069-20060307-C00036
The synthesis is carried out according to the protocol y. The dimethylformamide (dimethyl acetal) in excess is distilled off under reduced pressure and the enamino ester obtained is crystallized from ethyl acetate. The product is obtained in the form of orange-colored crystals.
(Yield>80%). (rf: CH2Cl2, 0.15). m.p.: 152° C. IR: 3374; 3415; 1700; 1671; 1596; 1518; 1394; 1318; 1252; 1218; 1199; 1110; 959. 1H NMR (CDCl3): 7.65 and 7.40 (2d, 2H, J=12.8, H5,4); 3.27 and 3.08 (2s, 6H, N—(CH3)2); 2.54 (s, 3H, 3-CH3) 1.66 (s, 6H, CH3). 13C NMR (CDCl3); CO: 169.5; CH; 103.6; CH3; 46.6; 36.6; 27.0; 19.2.
EXAMPLE 1g Synthesis of the Compound (1-s)
Figure US07009069-20060307-C00037
The synthesis is carried out according to the protocol y. The dimethylformamide (dimethyl acetal) is distilled off under reduced pressure. The product is obtained in the form of an orange yellow oil. Yield>75%.
IR: 1725; 1633; 1541; 1375; 1213; 1151; 1100; 1062; 860. 1H NMR (CDCl3): 7.53 (d, 1H, J=12.3, H3); 6.85–6.50 (m, 3H, H4+H5+H7); 5.23 (m, 1H, H6); 4.25 (2q, 4H, CH2); 2.92 (S, 6H, N—(CH)3); 1.33 (2t, 6H, CH3). 13C NMR (CDCl3) (CO) 166.6 and 166.3 (CH) 151.1; 151.0; 116 4; 110.0; 99.7 (CH3); 14.7.
EXAMPLE 1h Preparation of the Compound (1-t)
Figure US07009069-20060307-C00038
The synthesis is carried out according to the protocol y with dimethylacetamide (dimethyl acetal). The dimethylacetamide (dimethyl acetal) is distilled off under reduced pressure. The product is obtained in the form of a crystallized red product. Yield>50%.
1H NMR (CDCl3): 3.48 (s, 3H, CH3); 3.23 (s, 6H, N—(CH)3); 1.71 (s, 6H, C(CH3)2).
EXAMPLE 1i Synthesis of the Compound (1-u)
Figure US07009069-20060307-C00039
The synthesis is carried out according to the protocol y. Yield>40%.
IR: 2925; 2200; 1707; 1691; 1627; 1516; 1432; 1235; 1182; 1109; 1089; 1019. 1H NMR (CDCl3): 8.18 (d, 1H, J=13.2); 7.04 (d, 1H, J=13); 6.38 (d, 1H, J=13.2); 5.38 (d, 1H, J=13); 3.83 (s, 3H); 3.03 (s, 6H); 1.59 (s, 3H). 13C NMR (CDCl3) (CO) 165.7; (CN) 114.7; (CH) 151.0; 481.5; 117.7; 114.7 (CH3); 52.0; 13.9.
EXAMPLE 2 General Procedure for Preparing the Compounds of Formua (1) According to the Second Method EXAMPLE 2a Preparation of the Compound (1-v)
Figure US07009069-20060307-C00040
Under argon, 11 mmol of methyl cyanoacetate, 10 mmol of acetylacetaldehyde dimethyl acetal and 12 mmol of pyrrolidine in 100 ml of toluene are stirred for 1 h at room temperature and then under reflux for 6 h with a Dean-Stark type apparatus. The product crystallizes on cooling and is recrystallized from an ether-methanol mixture. Yellow crystals m.p. 162–64° C. Yield>65%.
IR: 3460; 2965; 2189; 1679; 1570; 1454; 1230. 1H NMR (CDCl3): 8.07 (d, 1H, J=13.5); 5.56 (d, 1H, J=13.5); 3.77 (s, 3H); 3.59 (m, 2H); 3.46 (m, 2H); 2.25 (s, 3H); 2.05 (m, 4H). 13C NMR (CDCl3) (CO) 166.6 (CH) 152.9; 97.9; CN 82.7; (CH2) 49.7; 49.1; 25.1; 24.7 (CH3); 51.6; 16.7.
EXAMPLE 2b Preparation of the Compound (1-w)
Figure US07009069-20060307-C00041
Under argon, 11 mmol of Meldrum's acid, 10 mmol of acetylacetaldehyde dimethyl acetal and 12 mmol of pyrrolidine in 100 ml of toluene are stirred for 1 h at room temperature and then under reflux for 6 h with a Dean-Stark type apparatus. The product crystallizes on cooling and is recrystallized from an ether-methanol mixture. Red crystals m.p. 218–22° C. (dec). Yield>35%.
IR: 3440; 2978; 1668; 1558; 1359; 1188. 1H NMR (CDCl3): 8.24 (d, 1H, J=14); 7.05 (d, 1H, J=14); 3.68 (m, 4H); 2.36 (s, 3H); 2.08 (m, 4H); 1.70 (s, 6H). 13C NMR (CDCl3) (CO) 166.9; 166.1 (CH) 152.0; 103.8; (CH2) 50.5; 50.1; 24.9; 24.5 (CH3); 25.8; 16.5.
EXAMPLE 2c Synthesis of the Compound (1-q) According to the Preceding Method with Dimethylamine Instead of Pyrrolidine
Figure US07009069-20060307-C00042
The enamino ester is crystallized from ether and it is obtained in the form of yellow crystals. (Yield>50%).
EXAMPLE 3a First Method (n Units to n+1 Units)
Under argon, 10 mmol of an alkylmagnesium halide, for example methylmagnesium chloride or bromide (3 M in tetrahydrofuran (THF)) are added at a temperature in the region of −10° C., to 10 mmol of enamine (1) comprising n units, for example the compound (1-j) in 20 ml of THF. The medium is left at room temperature for 1 h 30 min. The medium is cooled to around −0° C. and 1 ml of ethanol is added. The medium is slightly acidified with 1 M HCl and the impurities are extracted with ether. A basic medium is obtained by adding aqueous ammonia, at around 0° C. The medium is extracted with dichloromethane, washed with water and dried over sodium sulfate. The crude product is dissolved in 15 ml of toluene and heated for 30 min at boiling temperature. After evaporation under reduced pressure, the product is isolated. This product, treated with DMFDMA, makes it possible to prepare the compound of formula (1) comprising n+1 units.
EXAMPLE 3b Second Method (n Units to n+2 Units)
Under argon, 10 mmol of butyllithium are added at a temperature in the region of −25° C., to 10 mmol of diisopropylamine in 20 ml of THF. 10 mmol of ketone, in particular acetone, in 15 ml of THF, are slowly added. The stirring is maintained for 10 min, and 10 mmol of enamine (1) comprising n units or of enol ether (1) comprising n units, in 20 ml of THF, are added at around −30° C. The temperature is allowed to return to room temperature over 10 minutes and the medium is heated for 2 h 30 min under reflux (until the emission of dimethylamine ceases). The medium is cooled to a temperature between −10 and 0° C. and 20 mmol of methylmagnesium chloride (3 M in THF) are added. The reaction is allowed to return to room temperature. After stirring for 1 h 30 min, 1 ml of ethanol is added, at 0° C., and then the medium is acidified with 1 M HCl. It is extracted with dichloromethane, washed with 1 M HCl and then with water. After drying over MgSO4, the product is isolated after distillation of the solvents under reduced pressure. This product, treated with DMFDMA, makes it possible to prepare the compound of formula (1) comprising n+2 units.
EXAMPLE 3c Synthesis of the Compound (3-f)
Figure US07009069-20060307-C00043
Starting with the compound (1-j), the method of Example 3a is used.
Colorless oil. Yield 90%.
IR: 2960; 1723; 1638; 1591; 1435; 1307; 1224; 1065. 1H NMR (CDCl3): 6.77 (dq, 1H, J=15.5, j′=1.6, H4); 6.32 (dq, 1H, J=15.5, j′=6.8, H5); 3.77 and 3.78 (2s, 6H, COOCH3); 2.15 (s, 3H, 3-CH3); 1.89 (dd, 3H, J=6.8, J′=1.6, 5-CH3). 13C NMR (CDCl3): (CO); 166.2; 166.1 (CH); 136.4; 129.6 (CH3); 52.4; 52.1; 19.1; 16.0.
EXAMPLE 3d Synthesis of the Compound (3-e) (Example 5)
Figure US07009069-20060307-C00044
Starting with the compound prepared in Example 2, the method of Example 3a is used.
Rapid chromatography on silica rf: 0.8 (eluent: dichloromethane). Colorless oil Yield purified (80%).
IR (film): 2955; 1734; 1646; 1437; 1382; 1359; 1265; 1225; 1128; 1056. 1H NMR (CDCl3): 7.10 (q, 1H, J=7.3, H3); 3.80 (2s, 6H, OCH3); 1.93 (d, 3H, J=7.3 4-CH3). 13C NMR (CDCl3) (CO); 165.6; 164.2 (CH); 145.6 (CH2); 61.0 (CH3); 52.3; 15.5.
EXAMPLE 3e Synthesis of the Compound (3-g)
Figure US07009069-20060307-C00045
Starting with the compound (1-c), the method of Example 3a is used.
Rapid chromatography on silica rf: 0.8 (eluent: dichloromethane). Colorless oil Yield purified (80%). Mixture of isomers (1 very predominant, >95%).
IR (film): 2984; 2939; 1725; 1641; 1604; 1447; 1373; 1300; 1242; 1213; 1170; 1095; 1024; 979. 1H NMR (CDCl3): 7.35 (d, 1H, J=11.5, H3); 6.51 (dd, 1H, J=11.5, J=1.7 H4); 6.35 (m, 1H, H5); 4.30 (2q, 2H, J=7.2, CH2); 1.91 (d, 3H, J=6.8 6-CH3); 1.32 (2t, 3H, J=7.2, CH3); 13C NMR (CDCl3) (CO); 165.3; 164.7 (CH); 145.0; 144.2; 127.0 (CH2); 61.0 (CH3); 19.0; 14.0.
EXAMPLE 3f Synthesis of the Compound (3-h)
Figure US07009069-20060307-C00046
Starting with the compound (1-k), the method of Example 3a is used.
Rapid chromatography on silica rf: 0.8 (eluent: dichloromethane); Colorless oil Yield purified (80%).
IR (film): 2953; 1735; 1622; 1607; 1436; 1374; 1263; 1221; 1074; 1038. 1H NMR (CDCl3): 7.25 (s, 1H, H3); 6.11 (q, 1H, J=7.1, H5); 3.79 and 3.74 (2s, 6H, OCH3) 1.78 (d, 3H, J=7.1, 6-CH3); 1.70 (s, 3H, 4-CH3). 13C NMR (CDCl3) (CO); 167.5; 165.0 (CH); 147.1; 140.8 (CH3); 52.2; 14.6; 12.1.
EXAMPLE 3g Synthesis of the Compound (3-i)
Figure US07009069-20060307-C00047
Starting with the compound (1-j), the method of Example 3a is used.
Rapid chromatography on silica rf: 0.8 (eluent: dichloromethane. Colorless oil. Yield 90%.
1H NMR (CDCl3): 6.77 (dt, 1H, J=15.5, j′=1.5, H4); 6.34 (dt, 1H, J=15.5, j′=6.7, H5); 3.80 and 3.78 (2s, 6H, COOCH3); 2.22 (2dq, 2H, CH2, J=7.5, J=1.5); 2.17 (s, 3H, 3-CH3); 1.06 (t, 3H, J=7.5, 6-CH3). 13C NMR (CDCl3): (CO); 166.3; 166.1 (CH); 142.9; 127.3 (CH2); 26.4 (CH3); 52.1; 52.0; 16.0; 12.9.
EXAMPLE 3h Synthesis of the Compound (3-j)
Figure US07009069-20060307-C00048
Starting with the compound obtained in Example 1g, the method of Example 3a is used.
Rapid chromatography on silica rf: 0.8 (eluent: dichloromethane). Colorless oil Yield purified (80%).
IR (film): 2953; 1734; 1700; 1622; 1607; 1436; 1373; 1263; 1222; 1075; 1038. 1H NMR (CDCl3): 7.37 (d, 1H, J=11.6, H3); 6.64 (m, 1H, H5); 6.56 (m, 1H, H4); 6.18 (m, 1H, H6); 6.05 (m, 1H, H7); 4.24 (2q, 2H, J=7.1, CH2); 1.84 (d, 3H, J=6.8, 6-CH3); 1.32 (2t, 3H, J=7.1, CH3). 13C NMR (CDCl3) (CO); 165.3; 164.7 (CH); 145.3; 145.0; 137.6; 131.3; 123.8 (CH2); 61.0 (CH3); 18.6; 14.0.
EXAMPLE 3i Synthesis of the Deconjugated Isomer of the Compound (3-k) (Methyl Ester)
Figure US07009069-20060307-C00049
Starting with the compound (1-x), the method of Example 3b is used.
Colorless oil. Yield 60%.
IR: 2954; 1740; 1738; 1640; 1610; 1435; 1311; 1259; 1224; 1195; 1149; 1021; 962. 1H NMR (CDCl3): 6.38 (d, 1H, J=16, H5); 6.29 (d, 1H, J=16, H6); 5.81 (d, 1H, J=9.6, H3); 5.03 (2s, 2H, CH2); 4.44 (d, 1H, J=9.6, H2); 3.75 (s, 6H, COOCH3); 1.88 (s, 3H, 7-CH3); 1.86 (s, 3H, 4-CH3). 13C NMR (CDCl3): (CO); 168.4 (CH); 132; 131.8; 122.2; 51.4; (CH2); 117.3 (CH3); 52.7; 18.4; 18.0.
EXAMPLE 3j Synthesis of the Compound (3-l)
Figure US07009069-20060307-C00050
The compound (1-y) is obtained according to the technique used by H. Merwein Justus Liebigs Ann. Chem. 1961, 641, 1–39. Starting with it, the compound (3-l) is obtained according to the method described in Example 3b.
Beige crystals Yield>40%). m.p. 64–66° C.
IR (film): 2958; 2220; 1748; 1724; 1620; 1575; 1437; 1264; 1163; 1093; 762. 1H NMR (CDCl3): 8.16 (d, 1H, J=12.3); 6.52 (d, 1H, J=12.3); 3.89 (s, 3H); 2.06 (s, 3H); 2.02 (s, 3H). 13C NMR (CDCl3) (CO); 163.3; 114.6 (CN); (CH); 151.5; 122.7 (CH3); 52.8, 6; 27.4; 20.0.
EXAMPLE 4a Method of Converting a Compound of Formula (1-x) to the Corresponding Aldehyde (4-a)
Figure US07009069-20060307-C00051
0.01 mol of enamino ester (1-x) in 40 ml of dichloromethane and 40 ml of 1 M HCl are stirred for 6 h at room temperature. The organic phase is washed with water and dried over MgSO4. After distillation of the dichloromethane under reduced pressure, a colorless oil is obtained. Yield 95%.
IR: 3006; 2958; 2847; 1739; 1695; 1649; 1599; 1437; 1317; 1264; 1219; 1154; 1017. 1H NMR (CDCl3): 9.49 (s, 1H, CHO); 6.72 (dq, 1H, J=9.4, J′=1.4, H3); 4.54 (d, 1H, J=9.4, H2); 3.78 (s, 6H, CH3); 1.79 (d, 3H, 4-CH3). 13C NMR (CDCl3); (CO); 193.9 (CH); 141.6; 53.1; (CH3); 51.5; 9.5.
EXAMPLE 4b Method for Converting a Compound of Formula (1-j) to the Corresponding Aldehydes (4-b) and (4-c)
Figure US07009069-20060307-C00052
  • a) 0.01 mol of enamino ester in 40 ml of dichloromethane and 40 ml of 2 M HCl are stirred for 15 h at room temperature. The organic phase is washed with water and dried over MgSO4. After distillation of the dichloromethane under reduced pressure, a colorless oil consisting of 3 isomers is obtained. Yield 95%.
  • b) 0.01 mol of enamino ester in suspension in 40 ml of cyclohexane and 10 ml of formic acid are stirred for 2 h at room temperature. 100 ml of ice-cold water are added and the aqueous phase is extracted with ether. The organic phases are washed with water and dried over MgSO4. After distillation of the solvents under reduced pressure, a colorless oil consisting of 3 isomers is obtained Yield=(50%).
EXAMPLE 4c Method for Converting a Compound of Formula (1-u) to the Corresponding Aldehyde (4-d)
Figure US07009069-20060307-C00053
0.01 mol of enamino ester in 40 ml of dichloromethane and 40 ml of 2 M HCl are stirred for 18 h at room temperature. The organic phase is washed with water and dried over MgSO4. After distillation of the dichloromethane under reduced pressure, a colorless oil is obtained. Yield>25%.
IR (film): 2958; 2225; 1734; 1691; 1580; 1436; 1264; 1087; 1015; 801; 703. 1H NMR (CDCl3): 9.73 (s, 1H); 8.32 (d, 1H, J=12); 7.33 (d, 1H, J=12); 3.97 (s, 3H); 3.35 (s, 2H); 2.09 (s, 3H). 13C NMR (CDCl3) (CO); 193.4; (CH); 147.8; 137.8 (CH2); 53.5 (CH3); 53.6, 6; 10.9.
EXAMPLE 5 General Method for Synthesizing Retinoids
Under argon, 10 mmol of butyllithium are added at a temperature in the region of 25° C. to 10 mmol of diisopropylamine in 20 ml of dimethoxyethane (DME). 10 mmol of β-ionone in 20 ml of DME are slowly added at a temperature between −30 and −40° C. The stirring is maintained for 20 minutes and 10 mmol of the derivative (1), in which G represents a group —NR4R5 or OP, in 50 ml of DME are added. The medium is allowed to return to room temperature over 10 minutes and it is heated for 1 h under reflux (until the emission of dimethylamine ceases). The medium is cooled to a temperature between −10 and 0° C. and 20 mmol of alkyl- or arylmagnesium halide (3 M in THF) ae added. The medium is allowed to return to room temperature over 30 minutes and 15 ml of ethanol and then 5 equivalents of potassium hydroxide in 50 ml of water are added at 0° C. The medium is stirred for 30 minutes at room temperature and for 45 minutes at 40° C. The organic solvents are distilled off under reduced pressure. The medium is acidified with a 2 N ice-cold hydrochloric acid solution. It is extracted with ethyl acetate, washed with 1 M hydrochloric acid and then washed with water and dried over sodium sulfate.
EXAMPLE 6 “One Pot” Synthesis of Retinoic Acid (3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid)
Figure US07009069-20060307-C00054
The β-ionone is reacted with the compound (1-j) prepared in Example 1b according to the general method described in Example 5.
The yield after purification is equal to 61%.
The physicochemical characteristics are identical to those of a reference sample (SIGMA).
EXAMPLE 7 Preparation of the 9,12-dimethyl Analog of All-Trans-Retinoic Acid (4,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid)
Figure US07009069-20060307-C00055
The β-ionone is reacted with the compound (1-x) according to the general method described in Example 5. TLC: rf: 0.3 (CH2Cl2/MeOH 95/5).
The yield of crude product is equal to 75%.
The crude product is extracted with a saturated bicarbonate solution. After acidification and extraction with ether, the product is purified by chromatography on silica and obtained in the form of a yellow liquid.
The yield of purified product is equal to 25%.
IR: 2948; 2850; 1715; 1601; 1500; 1460; 1028; 756; 697. 1H NMR (CDCl3): 7.53 (d, 1H, J=15.4, H13); 6.83 (d, 1H, J=12.1, H13); 6.38 (m, 2H, H7+10); 6.23 (d, 1H, J=15.1, H8); 5.87 (d, 1H, J=15.4, H14): 2.03 (s, 3H, 12-CH3); 1.95 (s, 3H, 9-CH3); 1.94 (m, 2H, 3-CH2); 1.80 (s, 2H, 4-CH2); 1.75 (s, 3H, 3-CH3); 1.67 (m, 2H, 5-CH2); 1.05 (s, 3H, 6-CH3). 13C NMR (CDCl3) (CO); 185.6 (CH); 151.6; 137.6; 137.4; 136.1; 130.3; 125.4 (CH2); 39.5; 34.2; 19.1 (CH3); 30.9; 28.9; 12.7.
EXAMPLE 8 Preparation of the 13-Demethyl Analog of Retinoic Acid (7-methyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid)
Figure US07009069-20060307-C00056
The general method described in Example 5 is used. TLC: rf: 0.35 (CH2Cl2/MeOH 95/5). Yield after purification 7 g (52%).
The product is obtained in the form of a mixture of isomers in which the all-trans isomer is very predominant.

Claims (1)

1. A compound of the formula:
Figure US07009069-20060307-C00057
or an ethyl ester analog thereof.
US10/399,910 2000-10-26 2001-10-26 Intermediates for use in retinoid synthesis Expired - Fee Related US7009069B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/317,198 US7148372B2 (en) 2000-10-26 2005-12-27 Intermediates for use in retinoid synthesis
US11/317,200 US7323589B2 (en) 2000-10-26 2005-12-27 Intermediates for use in retinoid synthesis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0013726A FR2815961B1 (en) 2000-10-26 2000-10-26 NEW INTERMEDIATES USEFUL FOR RETINOID SYNTHESIS
FR00/13726 2000-10-26
PCT/FR2001/003331 WO2002034710A2 (en) 2000-10-26 2001-10-26 Novel intermediates for use in retinoid synthesis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/317,198 Division US7148372B2 (en) 2000-10-26 2005-12-27 Intermediates for use in retinoid synthesis
US11/317,200 Division US7323589B2 (en) 2000-10-26 2005-12-27 Intermediates for use in retinoid synthesis

Publications (2)

Publication Number Publication Date
US20040132796A1 US20040132796A1 (en) 2004-07-08
US7009069B2 true US7009069B2 (en) 2006-03-07

Family

ID=8855754

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/399,910 Expired - Fee Related US7009069B2 (en) 2000-10-26 2001-10-26 Intermediates for use in retinoid synthesis
US11/317,200 Expired - Fee Related US7323589B2 (en) 2000-10-26 2005-12-27 Intermediates for use in retinoid synthesis
US11/317,198 Expired - Fee Related US7148372B2 (en) 2000-10-26 2005-12-27 Intermediates for use in retinoid synthesis

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/317,200 Expired - Fee Related US7323589B2 (en) 2000-10-26 2005-12-27 Intermediates for use in retinoid synthesis
US11/317,198 Expired - Fee Related US7148372B2 (en) 2000-10-26 2005-12-27 Intermediates for use in retinoid synthesis

Country Status (9)

Country Link
US (3) US7009069B2 (en)
EP (1) EP1328506B1 (en)
JP (1) JP4334868B2 (en)
AT (1) ATE286017T1 (en)
CA (1) CA2427043C (en)
DE (1) DE60108153T2 (en)
ES (1) ES2234914T3 (en)
FR (1) FR2815961B1 (en)
WO (1) WO2002034710A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100035839A1 (en) * 2006-10-13 2010-02-11 Ciba Corporation Merocyanine derivatives

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2416351A (en) * 2004-06-29 2006-01-25 Ciba Sc Holding Ag Use of myocyanine derivatives for the protection of human hair and skin from UV radiation
JP4864623B2 (en) * 2006-09-27 2012-02-01 富士フイルム株式会社 Method for producing δ-aminopentadienoic acid ester derivative
DE102008002302A1 (en) 2007-06-13 2008-12-18 Basf Se Preparing etretinate, useful to treat severe psoriasis and ichthyosis vulgaris, comprises reacting acitretin with active reagent e.g. 1,1'-carbonyldiimidazole, followed by reacting with ethanol and/or alkali or alkaline earth ethanolate
US8158964B2 (en) * 2009-07-13 2012-04-17 Seagate Technology Llc Schottky diode switch and memory units containing the same
BR112014001418B1 (en) 2011-07-21 2021-05-11 Basf Se compounds, and, process for preparing the compounds
WO2013010590A1 (en) 2011-07-21 2013-01-24 L'oreal Cosmetic and/or dermatological composition containing a merocyanine derivative comprising specific polar groups consisting of hydroxyl- and ether-functionalities
FR3001216B1 (en) 2013-01-21 2015-02-27 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE, AN OILY PHASE AND A C4 MONO-ALKANOL
FR3001138B1 (en) 2013-01-21 2015-06-19 Oreal COSMETIC OR DERMATOLOGICAL ANHYDROUS COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE
FR3001133B1 (en) 2013-01-21 2015-03-20 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE COMPRISING AT LEAST ONE PARTICULATE AMIDE COMPOUND
FR3046928B1 (en) 2016-01-26 2019-08-09 L'oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE COMPRISING AT LEAST ONE N-SUBSTITUTED AMIDE
FR3046929B1 (en) 2016-01-26 2018-03-02 L'oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE COMPRISING AT LEAST ONE DI OR TRICARBOXYLIC ACID ESTER
FR3046930B1 (en) 2016-01-26 2018-03-02 L'oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE COMPRISING AT LEAST ONE POLYALKYLENE GLYCOL
FR3046927B1 (en) 2016-01-26 2018-03-02 L'oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE COMPRISING AT LEAST ONE ISOSORBIDE ETHER
FR3083097B1 (en) 2018-06-28 2020-11-27 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE CONTAINING AT LEAST ONE ALKYL OR ALKYLENE CARBONATE
FR3117825A1 (en) 2020-12-18 2022-06-24 L'oreal Cosmetic or dermatological composition comprising a merocyanine, a triazine UV filter, and a polysaccharide modified by hydrophobic chains
FR3117824A1 (en) 2020-12-18 2022-06-24 L'oreal Cosmetic or dermatological composition comprising a merocyanine and an oily phase comprising at least one citric acid ester

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1055849A (en) 1950-04-22 1954-02-22 Eastman Kodak Co New process for the synthesis of polyene carotenoids
DE1046612B (en) 1957-10-23 1958-12-18 Basf Ag Process for the production of vitamin A and its biologically active derivatives
DE1559900A1 (en) 1966-11-09 1970-03-05 Hettich Paul & Co Invisible hinge
DE2816226A1 (en) 1977-04-15 1978-10-26 Fuji Photo Film Co Ltd SILVER HALOGENIDE PHOTOGRAPHIC MATERIAL CONTAINING AN ULTRAVIOLET LIGHT ABSORBING AGENT AND A METHOD FOR REDUCING THE EFFECT OF ULTRAVIOLET LIGHT ON THE SILVER HALOGENIDE PHOTOGRAPHIC MATERIAL
EP0802180A1 (en) 1994-12-16 1997-10-22 Centre National De La Recherche Scientifique Beta-methylene aldehydes particularly useful for the preparation of valuable compounds such as retinoids or carotenoids and preparation of valuable compounds by means of those beta-methylene aldehydes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1059900B (en) * 1957-09-03 1959-06-25 Basf Ag Process for the preparation of compounds of the vitamin A series

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1055849A (en) 1950-04-22 1954-02-22 Eastman Kodak Co New process for the synthesis of polyene carotenoids
DE1046612B (en) 1957-10-23 1958-12-18 Basf Ag Process for the production of vitamin A and its biologically active derivatives
DE1559900A1 (en) 1966-11-09 1970-03-05 Hettich Paul & Co Invisible hinge
DE2816226A1 (en) 1977-04-15 1978-10-26 Fuji Photo Film Co Ltd SILVER HALOGENIDE PHOTOGRAPHIC MATERIAL CONTAINING AN ULTRAVIOLET LIGHT ABSORBING AGENT AND A METHOD FOR REDUCING THE EFFECT OF ULTRAVIOLET LIGHT ON THE SILVER HALOGENIDE PHOTOGRAPHIC MATERIAL
US4195999A (en) 1977-04-15 1980-04-01 Fuji Photo Film Co., Ltd. Silver halide photographic material containing ultraviolet light absorbing agent
EP0802180A1 (en) 1994-12-16 1997-10-22 Centre National De La Recherche Scientifique Beta-methylene aldehydes particularly useful for the preparation of valuable compounds such as retinoids or carotenoids and preparation of valuable compounds by means of those beta-methylene aldehydes
US5925797A (en) 1994-12-16 1999-07-20 Centre National De La Recherche Scientifique (Cnrs) β-methylene aldehydes and preparation of compounds of interest by means of the β-methyl aldehydes

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
Ber. Bunsen-Ges. Phys. Chem., vol. 80, 1976, pp. 630-636.
Bull, Acad. Sci. USSR Div. Chem. Sci. vol. 22, 1973, pp. 1963-1971.
Bull. Acad. Sci. USSR Div. Chem. Sci., vol. 22, 1973, pp. 2478-2482.
Bull. Acad. Sci. USSR Div. Chem. Sci., vol. 24, 1975, pp. 2397-2401.
Bull. Acad. Sci. USSR Div. Chem. Sci., vol. 29, 1980, pp. 1643-1651.
Bull. Acad. Sci. USSR Div. Chem. Sci., vol. 39, No. 2.1, 1990, pp. 298-306.
Bull. Acad. Sci. USSR Div. Sci., vol. 30, No. 2, 1981, pp. 308-311.
Chem. Heterocycl. Compd., vol. 24, No. 10, 1988, pp. 1095-1103.
Ivz. Akad. SSSR, 1972, pp. 2153-2218.
Journal of Organic Chemistry, vol. 64, No. 26, 1999, pp. 9493-9498.
Journal of the American Chemical Society, vol. 115, No. 7, 1993, pp. 3006-3007.
Journal of the American Chemical Society, vol. 116, No. 6, 1994, pp. 2619-2620.
Pharmazie, vol. 54, No. 8, 1999, pp. 571-574.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100035839A1 (en) * 2006-10-13 2010-02-11 Ciba Corporation Merocyanine derivatives
US9068080B2 (en) 2006-10-13 2015-06-30 Basf Se Merocyanine derivatives

Also Published As

Publication number Publication date
EP1328506B1 (en) 2004-12-29
DE60108153T2 (en) 2005-12-08
JP2004530636A (en) 2004-10-07
FR2815961A1 (en) 2002-05-03
EP1328506A2 (en) 2003-07-23
US20040132796A1 (en) 2004-07-08
CA2427043C (en) 2012-12-04
ATE286017T1 (en) 2005-01-15
WO2002034710A3 (en) 2002-07-04
DE60108153D1 (en) 2005-02-03
ES2234914T3 (en) 2005-07-01
WO2002034710A2 (en) 2002-05-02
US20060135808A1 (en) 2006-06-22
FR2815961B1 (en) 2008-11-28
CA2427043A1 (en) 2002-05-02
JP4334868B2 (en) 2009-09-30
US7148372B2 (en) 2006-12-12
US20060106245A1 (en) 2006-05-18
US7323589B2 (en) 2008-01-29

Similar Documents

Publication Publication Date Title
US7009069B2 (en) Intermediates for use in retinoid synthesis
CA1058625A (en) Manufacture of symmetrical carotenoids
EP0298404B1 (en) Sulfon polyenes
US5424478A (en) Process for producing vitamin A derivatives
CN111108086A (en) Novel intermediates for vitamin A synthesis
JP2008544955A (en) Catalytic scriabin reaction
US6187959B1 (en) Preparation of phosphonium salts
US3558712A (en) Method for the synthesis of zeaxanthins,xanthophylis,and 3-oxo-beta carotene
KR101950048B1 (en) NEW INTERMEDIATES FOR THE VITAMIN A AND β-CAROTENE SYNTHESIS
US6423873B1 (en) Process for preparing phosphonium salts
JP3961136B2 (en) Production of polyene aldehyde
JPH029857A (en) Production of halosulfone
US4009202A (en) 2(or 3)-methyl-1-acetoxy-4-alkoxy (or phenoxy)-1,3-butadienes
US5925797A (en) β-methylene aldehydes and preparation of compounds of interest by means of the β-methyl aldehydes
KR101939863B1 (en) Process for the production of 1,3,3-trimethyl-2-(3-methylpent-2-en-4-ynyl)cyclohex-1-ene
US5567855A (en) Methods for stereospecific synthesis of polyene aldehydes
US4048234A (en) Sulphones
KR102133791B1 (en) Novel intermediates for preparing norbixin or bixin ethyl ester and methods thereof
US3830844A (en) Method for synthesizing rhodoxanthin
US3890393A (en) 2-Methyl-butadienyl-sulphones
Ballester et al. Unsaturated carboxylic acid dienolates. Reaction with substituted cyclohexanones and unsubstituted cycloalkanones. Regio-and stereo-selectivity
US7524983B2 (en) Catalytic scriabine reaction
EP1948584B1 (en) Process for the preparation of cyclopentanone derivatives
KR101525491B1 (en) Preparation method of benzoannulene derivatives by Using intramolecular Cycloreduction
EP0839788A1 (en) Stereospecific synthesis of polyene compounds

Legal Events

Date Code Title Description
AS Assignment

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VALLA, ALAIN;CARTIER, DOMINIQUE;LABIA, ROGER;AND OTHERS;REEL/FRAME:015459/0224;SIGNING DATES FROM 20040528 TO 20040605

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.)

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20180307

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载